Artikel
Human fetal striatal transplantation in Huntington's disease. The first Italian clinical trial
Suche in Medline nach
Autoren
Veröffentlicht: | 30. Mai 2008 |
---|
Gliederung
Text
Objective: We report on preliminary results of the first Italian clinical trial in Human Fetal Striatal Transplantation (HFST) in Huntington’s Disease (HD).
Methods: After approval of the National Ethics Committee, eight clinically and genetically defined HD patients underwent HFST at our institution. Subject selection, enrollment and evaluation followed a modified version of the Core Assessment Program for Intracerebral Transplantation (CAPIT).
Seven patients received bilateral grafts in two sessions 1 month apart, while one patient has not received the contralateral graft yet. A cell suspension obtained from the whole ganglionic eminence of a 9-12 weeks post-conception fetus was implanted in the head of the caudate nucleus and in the pre- and post-commissural putamen by means of an image-guided robotic-assisted stereotactic procedure. For each procedure five to nine stereotactic tracks were performed. Striatal atrophy prevented grafting of the posterior putamen in four out of fifteen procedures. Immunosuppression was started one day before the first grafting with cyclosporin A, prednisolone and azathioprine.
Results: The procedure resulted feasible and well tolerated. In all patients, post-operative MR imaging did not detect any complication related to surgery and showed the needle tracks and appropriate location of grafted material within the targets.
Follow-up ranged from 2 to 18 months. Patient 2 experienced, one month after each procedure, the occurrence of a subdural haematoma necessitating surgical evacuation. Seven patients show a slight improvement in their neurological status and in daily living activities, while one patient is clinically stable.
In patient 1, MR and 18-FDG PET studies show the neo-generation of metabolically active tissue with striatum-like imaging features. In other patients imaging findings are consistent with grafted tissue survival and growth.
Conclusions: HFST in HD is a feasible and safe procedure. Neuroimaging data suggest grafted tissue survival and growth. Based on early follow-up a clinical improvement, or at least a prevention of disease progression, can be achieved. Longer follow-up and a larger number of patients are needed to assess the efficacy of HFST in HD.